Transforming Biomanufacturing: Jacobs Delivers North America’s Largest Cell Culture Site
Delivering the largest end-to-end cell culture facility in North America

Credit: FUJIFILM Biotechnologies
Jacobs is providing Engineering Procurement Construction Management services for FUJIFILM Biotechnologies’ $3.2 billion Holly Springs campus – the largest end-to-end cell culture contract development and manufacturing organization (CDMO) site in North America. Designed to strengthen supply chain resilience and bring therapies closer to patients, the facility integrates drug substance manufacturing, automated fill-finish and large-scale packaging. With nearly 13 million hours worked, the project sets a new standard for safe, scalable delivery.
CDMOs driving biopharma growth
With global biopharma spending projected to hit $2 trillion by 2028, companies are turning to CDMOs to expand capacity and accelerate access to life-changing therapies. The Holly Springs facility demonstrates how FUJIFILM Biotechnologies, supported by Jacobs’ EPCM delivery model, is meeting this demand through modular design, regulatory expertise and rapid scale-up capabilities.
Accelerating delivery through digital innovation
Jacobs is using digital delivery and modular replication to reduce timelines, costs and complexity. The Holly Springs campus was intentionally designed as a model facility to support replication in Hillerød, Denmark. Jacobs’ team designed concurrent compliance with both U.S. and Danish building codes. This “design one, build many” approach, supported by data-driven execution and 4D schedule modeling, has enabled seamless transfer of designs across geographies while maximizing prefabrication components. This approach has already reduced indirect costs and delivered an estimated 70% efficiency gain between project phases – potentially establishing a replicable model for global biomanufacturing.
-
Fujifilm biomanufacturing facility. Credit: FUJIFILM Biotechnologies
-
Fujifilm biomanufacturing facility. Credit: FUJIFILM Biotechnologies
-
Fujifilm biomanufacturing facility. Credit: FUJIFILM Biotechnologies
Expanding capacity to meet global demand
Building on the success of phase one, Jacobs was selected to design and build the $1.2 billion expansion of the Holly Springs campus, announced in 2024. This second phase will add approximately 400,000 square feet of manufacturing space and eight additional 20,000-liter bioreactors, doubling the site’s large-scale production capacity. By leveraging the same digital replication strategies and integrated delivery model established in phase one, Jacobs and FUJIFILM Biotechnologies are ensuring consistency, efficiency and speed-to-market as the facility scales to meet global demand for advanced biologics.
Collaboration as a catalyst
Built on trust and transparency, the program applies a “best athlete” team approach, uniting expertise across disciplines to deliver at scale. This collaborative model enables innovation, agility and consistent problem-solving, ensuring momentum and performance across the project lifecycle.
“Our partnership with Jacobs has been instrumental in bringing our vision for Holly Springs to life. The work at this facility will be essential to helping our partners ensure supply chain agility and supplying medicines to patients in need. By combining Jacobs’ world-class expertise with our knowledge in biomanufacturing, we have created a foundation for resilient, large-scale production that will serve the healthcare community for decades to come.”
Advancing life sciences globally
Jacobs works with leading biopharma and CDMOs worldwide to design and deliver facilities that accelerate breakthrough therapies. Through EPCM delivery, modular replication and digital execution, Jacobs helps clients expand capacity and bring medicines to patients faster – with safety, sustainability and compliance at the core.
“Jacobs' collaboration with FUJIFILM Biotechnologies on the $3.2 billion Holly Springs large-scale biologics facility exemplifies the next generation of delivery models and innovation in this space – uniting technical precision, operational agility, and market responsiveness to accelerate the production of high-quality medicines and therapies at unprecedented scale, safely and consistently.”
Meet some of the team involved
-
Lindsay Gerding
Senior Vice President and General Manager, Jacobs
Lindsay drives Jacobs’ delivery of advanced biomanufacturing facilities that expand capacity and accelerate global health innovation.
-
Glenn Wakefield
VP, Executive Program Director
Glenn leads Jacobs’ delivery of this large-scale biomanufacturing campus.
-
Steve Ingle
VP, Construction Director, Life Sciences North America
Steve oversees construction execution, safety and quality for the project.
-
200
tons of dynamite used to level the project site
-
~ 13 M
hours the team has surpassed with a TRIR rate of 0.06, 25x better than industry average
-
10 M
Pounds of equipment received for phase one
-
8
x 20,000 cell culture bioreactors in phase one; each bioreactor is three-stories tall